Sanofi India is currently trading at Rs. 2261.00, up by 40.10 points or 1.81% from its previous closing of Rs. 2220.90 on the BSE.
The scrip opened at Rs. 2241.00 and has touched a high and low of Rs. 2261.00 and Rs. 2241.00 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 2450.00 on 31-Jan-2013 and a 52 week low of Rs. 2002.10 on 07-Jun-2012.
Last one week high and low of the scrip stood at Rs. 2317.95 and Rs. 2210.00 respectively. The current market cap of the company is Rs. 5090.00 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 27.37% and 12.23% respectively.
Sanofi India has launched Combiflam Plus, a targeted, fast and effective solution for headaches, which is also gentle on the stomach. Combiflam Plus is a combination of paracetamol and caffeine which is a targeted solution for headaches. A line extension of one of Sanofi India’s flagship brands Combiflam, the launch of this new product marks the company’s foray into the OTC headache segment in India.
This combination has 89% incremental analgesic effect in terms of total pain relief when compared with paracetamol monotherapy. Further Caffeine has been shown to have a synergistic and well documented adjuvant action when combined with analgesics (painkillers). Research shows that adding caffeine to an analgesic for e.g. paracetamol increases the potency of the analgesic by approximately 40%.
In a first of its kind ‘Pack of 4s’ packaging in the headache category, Combiflam Plus is priced at Rs 9.50 (MRP) and will be available in the states of Uttar Pradesh, Maharashtra, Tamil Nadu, West Bengal, Punjab and Haryana.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
